Skip to content

Role of Magnesium in Pediatric Cochlear Implant

Combination of Magnesium Sulphate With Total Intravenous Anesthesia Optimized Surgical Field in Pediatric Cochlear Implant Surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03722940
Enrollment
66
Registered
2018-10-29
Start date
2014-06-01
Completion date
2018-08-01
Last updated
2019-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Brief summary

To determine the efficiency of addition of magnesium sulfate to total intravenous anesthesia (TIVA) in optimizing the surgical field during pediatric cochlear implant surgery. Also its effects on the intraoperative evoked stapedial reflex thresholds (ESRT) and the intraoperative anesthetic requirements were evaluated.

Detailed description

Sixty-six ASA I and II children (1-6 years) undergoing cochlear implantation under general anesthesia were enrolled in this double blind, randomized study. Children were randomly allocated into two equal groups. Children in Group M (magnesium sulphate group) received an iv bolus dose of magnesium sulfate 40 mg Kg-1 over 5 minutes before induction of anesthesia followed by 15mg Kg-1 h-1 infusion until the start of skin closure. Children in Group C (Control group) received equivalent volumes of isotonic saline solution over the same period instead of magnesium sulphate. Haemodynamic variables, quality of surgical field, ESRT and the intraoperative anesthetic requirements were recorded

Interventions

DRUGMagnesium sulphate

Before induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.

Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of magnesium sulphate.

Sponsors

Bahteem Specialized Hospital
CollaboratorOTHER
Wahba bakhet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* ASA I and II children

Exclusion criteria

* uncontrolled hypertension, * diabetes mellitus, * liver disease, * kidney disease, * heart disease, * allergy to magnesium sulphate,

Design outcomes

Primary

MeasureTime frameDescription
Quality of surgical fieldat the end of the surgeyusing Fromme's-Boezaart scale (0 to 5). A score of ≤ 2 was considered to be optimal

Secondary

MeasureTime frameDescription
The anesthesia time.IntraoperativeMinutes
ESRT responsesAfter insertion of the electrode and after reversal of any residual muscle relaxant (TOF response > 0.9),the surgeon assessed ESRT response at the basal, middle, and apical areas of the electrode array by visual monitoring of the stapedius muscle using direct microscopic examination
The operative timeIntraoperativeMinutes
Mean arterial blood pressureIntraoperativemm Hg
Anesthetic consumptionIntraoperativepropofol and fentanyl requirement after the bolus
Heart ratebaseline, after surgical incision, Hypotensive period, after LMA removal and at recovery room admission.beats per minute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026